Literature DB >> 8324130

Wound and intraabdominal infections: microbiological considerations and approaches to treatment.

R L Nichols1, J W Smith.   

Abstract

Aerobic and anaerobic bacteria normally found in the human endogenous gastrointestinal microflora are the most frequent isolates from both postoperative incisional infections and intraabdominal infections. Experimental and clinical studies of intraabdominal infections have shown that many factors are important for successful treatment. Most important is rapid diagnosis followed by a carefully chosen and performed operation. The initial choice of antibiotics with both aerobic and anaerobic coverage has been associated with a high level of therapeutic success in both clinical and experimental settings. In addition, patients with severe intraabdominal infections appear to benefit from a scheduled postoperative relaparotomy with irrigation and exploration, which is most often done today with a zipper technique and which reduces the bacterial burden within the peritoneal cavity. The use of this approach may facilitate the action of properly chosen and administered parenteral antibiotics.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324130     DOI: 10.1093/clinids/16.supplement_4.s266

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.

Authors:  M L Peterson; L B Hovde; D H Wright; G H Brown; A D Hoang; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin.

Authors:  R Bachoual; L Dubreuil; C J Soussy; J Tankovic
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

3.  Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.

Authors:  D R Snydman; N V Jacobus; L A McDermott; S Supran; G J Cuchural; S Finegold; L Harrell; D W Hecht; P Iannini; S Jenkins; C Pierson; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.

Authors:  D J Walters; J S Solomkin; J A Paladino
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

5.  Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.

Authors:  M L Peterson; L B Hovde; D H Wright; A D Hoang; J K Raddatz; P J Boysen; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

6.  Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections.

Authors:  P Kempf; A Bauernfeind; A Müller; J Blum
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

Review 7.  [Diagnosis and therapy of sepsis. Guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine].

Authors:  K Reinhart; F Brunkhorst; H Bone; H Gerlach; M Gründling; G Kreymann; P Kujath; G Marggraf; K Mayer; A Meier-Hellmann; C Peckelsen; C Putensen; M Quintel; M Ragaller; R Rossaint; F Stüber; N Weiler; T Welte; K Werdan
Journal:  Internist (Berl)       Date:  2006-04       Impact factor: 0.743

8.  Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)).

Authors:  K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte
Journal:  Ger Med Sci       Date:  2010-06-28

9.  National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; Y Golan; E J C Goldstein; S M Finegold; L J Harrell; D W Hecht; S G Jenkins; C Pierson; R Venezia; V Yu; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

10.  Active efflux of norfloxacin by Bacteroides fragilis.

Authors:  S Miyamae; H Nikaido; Y Tanaka; F Yoshimura
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.